Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GS-9137- A Novel HIV-1 Integrase Inhibitor · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| GS-9137 - A Novel HIV-1 Integrase Inhibitor | DRUG | - |
Inclusion Criteria: * HIV RNA greater than or equal to 1000 c/mL. * Failed/Failing protease inhibitor based antiretroviral therapy. * Stable antiretroviral therapy for greater than or equal to 30 days prior to screening. * Negative Serum Pregnancy Test. * GFR by Cockcroft Gault greater than or equa...
GS-9137 is an investigational small molecule developed by Gilead Sciences, Inc. (ticker: GILD) for the treatment of HIV. It is described as a novel HIV-1 integrase inhibitor and has been studied in a Phase 2 clinical trial. It is not yet approved and remains in clinical development.
GS-9137 is being developed for the treatment of HIV, including HIV-1 and human immunodeficiency virus infection. It was studied in adults aged 18 years and older, including participants in the United States and Puerto Rico, as part of combination antiretroviral therapy regimens.
GS-9137 is developed by Gilead Sciences, Inc., which trades under the ticker GILD. Gilead is the sponsor of the clinical program evaluating the compound in HIV.
GS-9137 is in Phase 2 clinical development. It is an investigational agent and has not been approved by the FDA. The Phase 2 trial has been completed, and no active trials are currently listed for this asset.
GS-9137 was evaluated in one completed Phase 2 trial, NCT00298350, titled Ritonavir-Boosted GS-9137 vs. Ritonavir-Boosted Protease Inhibitor(s) in Combination With Background ART. The trial enrolled 278 participants with HIV, HIV-1, or human immunodeficiency virus infection and was conducted in the United States and Puerto Rico.
Yes. GS-9137 and GS-9137 - A Novel HIV-1 Integrase Inhibitor refer to the same investigational compound. The longer name is a descriptive title used for the asset, while GS-9137 is the shorter designation used in clinical trial listings and development references.